XNAS · ASND

+0.00% · +$0.0000 · Vol Not reported

Market closed · last close shown

Ascendis Pharma A/S Ordinary Share

$255.41

Card

Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factors

Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET · ASND

Methodology

ASND

Ascendis Pharma A/S Ordinary Share

Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET

44/100

SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

44/ 100

Veridion Score

SELL BIAS · HIGH confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: HIGH · 6/6 factors with data · Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is ASND moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move ASND next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Aug 7
Score
Score moved +10
34/SELL BIAS -> 44/SELL BIAS
Veridion score historySource
Oct 5
CongressChecking access
Gary Palmer sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Aug 6
CongressChecking access
Gary Palmer purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jul 12
CongressChecking access
Gary Palmer purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Ascendis Pharma A/S Ordinary Share

Listed since

2026

Employees

Country

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$255.41

Last session

Day high

$255.41

Last session

Day low

$255.41

Last session